Mesa Laboratories MLAB Biopharmaceutical Development — Cost Of Revenue Other

Similar metrics at other companies

VCYTBiopharmaceutical and other revenue — Cost of Revenue

$8K-99.7%

VCYTBiopharmaceutical and other revenue — Other cost

$8K-99.2%

LHBiopharma Laboratory Services — Other Cost and Expense, Operating

$89.7M-0.3%

ASHLife Sciences — Cost Of Revenue

$109M-6.8%

ANABBiopharma Company — Research And Development Expense Excluding Acquired In Process Cost

$34.9M-8.4%

FLGTTherapeutic Development — Cost Of Revenue

$8K—

Questions, answered.

What is Mesa Laboratories's biopharmaceutical development — cost of revenue other?

Mesa Laboratories (MLAB) reported biopharmaceutical development — cost of revenue other of $3.2M in Q1 2026.

How has Mesa Laboratories's biopharmaceutical development — cost of revenue other changed year-over-year?

Mesa Laboratories's biopharmaceutical development — cost of revenue other decreased by 35.4% year-over-year, from $4.95M to $3.2M.

What is the long-term trend for Mesa Laboratories's biopharmaceutical development — cost of revenue other?

Over 2 years (2024 to 2026), Mesa Laboratories's biopharmaceutical development — cost of revenue other has grown at a 15.2% compound annual growth rate (CAGR), from $13.75M to $18.25M.

What does biopharmaceutical development — cost of revenue other mean?

Includes all direct costs associated with generating revenue in the Biopharmaceutical Development segment that are not classified as depreciation or amortization. This typically encompasses direct labor, raw materials, and overhead costs directly linked to the production of goods or delivery of services. It provides insight into the variable cost structure of the segment's core operations.